Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
A kit for mucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate mucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH.
1. A kit for administering a mucosally absorbable composition to a human patient, comprising a first compartment comprising a first composition containing a substantially water-soluble pharmaceutical active agent comprising nalbuphine hydrochloride in a solution together with one or more optional suitable pharmaceutical excipients; and a second compartment comprising a second composition with one or more optional suitable pharmaceutical excipients, at least one of the first and second compositions containing an effective amount of a crystallization inhibitor; wherein the first and second compartments maintain separation of the first and second compositions during storage and allow for mixing of the first and second compositions to form a mucosally absorbable gel composition for immediate mucosal administration to a human patient to an intranasal site, wherein the second composition in the second compartment is at a basic pH and contains an alkaline buffer and the mucosally absorbable gel composition has a pH>7, and wherein the first and second compositions are configured to provide the nalbuphine hydrochloride in a state of supersaturation immediately after the mixing of the first and second compositions invoked by a rapid change in solubility effected by pH change.
2. The kit for administering a mucosally absorbable composition of claim 1 , where the mucosally absorbable gel composition is a supersaturated solution for >10 minutes.
3. The kit of claim 1 , wherein Tmax is achieved in less than twenty minutes when nalbuphine hydrochloride is administered intranasally.
4. The kit of claim 1 , wherein Tmax is achieved in less than fifteen minutes when nalbuphine hydrochloride is administered intranasally.
5. The kit of claim 1 , wherein Tmax is achieved in less than ten minutes when nalbuphine hydrochloride is administered intranasally.
6. The kit of claim 1 , wherein bioavailability of nalbuphine hydrochloride of approximately or greater than 25% relative to parenterally administered drug is achieved when nalbuphine hydrochloride is administered intranasally.
7. The kit of claim 1 , wherein Tmax is achieved in less than thirty minutes when nalbuphine hydrochloride is administered intranasally.